| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5592817 | Cardiovascular Revascularization Medicine | 2016 | 25 Pages |
Abstract
Post marketing use of Zilver® PTX® for the treatment of FP lesions is associated with lower patency rates compared with clinical trial data. This may be related to the high prevalence of TASC II class C or D lesions and ISR in real world practice. Future studies should be more representative of contemporary clinical practice.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Molecular Medicine
Authors
Won Yu Kang, Umberto Campia, Romain J. Didier, Sarkis Kiramijyan, Edward Koifman, Smita I. Negi, Michael J. Lipinski, Nevin C. Baker, Ricardo O. Escarcega, Rebecca Torguson, Ron Waksman, Nelson L. Bernardo,